Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease.
The pharmacology of cefotaxime and the metabolite desacetyl cefotaxime was studied in 40 patients with various degrees of renal and hepatic failure who received 0.5 or 1 g of cefotaxime intravenously. Patients with severe renal impairment (creatinine clearance, 3 to 10 ml/min) had a cefotaxime serum...
Збережено в:
| Опубліковано в:: | Antimicrob Agents Chemother |
|---|---|
| Автори: | , , |
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
American Society for Microbiology (ASM)
1981
|
| Предмети: | |
| Онлайн доступ: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC181470/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6264849/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.19.4.526 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|